Clinical Trial: Pomalidomide for Kaposi Sarcoma in People With or Without HIV Sponsor and CollaboratorsNational Cancer Institute (NCI) Principal InvestigatorRobert Yarchoan, MD, National Cancer Institute (NCI) ClinicalTrials.gov IdentifierNCT01495598Continue Reading
Patients with soft-tissue sarcoma who have an early PET response after initial chemotherapy survive longer than patients showing no such response.
Drug inhibits process that fuels tumor growth.
Phase 2 study shows overall response rate of 31 percent in patients with poor-prognosis HIV-KS.
Implanted immune system cells combined with radiation safely induced antitumor immune responses in patients with high-risk soft-tissue sarcomas.
A diagnosis of soft-tissue sarcoma can leave many patients unsure of what to do next. This fact sheet provides more information about this type of cancer and lists sources of support.
Continued skin surveillance is important for survivors of cutaneous melanoma (CM), indicate findings showing that this is the most common second primary cancer among persons with a first CM.
Compared with the general population, recipients of a kidney, liver, heart, or lung transplant have twice as great a risk for diverse infection-related and unrelated cancers.
A specific genetic alteration has been identified as a defining feature of epithelioid hemangioendothelioma (EHE), a vascular sarcoma that strikes about 100 people nationwide each year.
The experimental agent cediranib shrank tumors in more than half of study subjects afflicted with alveolar soft part sarcoma (ASPS).
